Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microba Life SciencesASX:MAP EV-to-EBITDA is -1.67 as of Jul. 31, 2026. The stock has 6 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, Microba Life Sciences ranks worse than 840335.29% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Microba Life Sciences's enterprise value is A$25.69 Mil.
Microba Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-15.40 Mil. Therefore, Microba Life Sciences's EV-to-EBITDA for today is -1.67.
The historical rank and industry rank for Microba Life Sciences's EV-to-EBITDA or its related term are showing as below:
ASX:MAP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.32 Med: -2.97 Max: -0.2
Current: -1.67
During the past 4 years, the highest EV-to-EBITDA of Microba Life Sciences was -0.20. The lowest was -8.32. And the median was -2.97.
ASX:MAP's EV-to-EBITDA is ranked worse than 100% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.76
vs ASX:MAP: -1.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Microba Life Sciences (ASX:MAP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Microba Life Sciences's PE Ratio (TTM) for today is calculated as:
Microba Life Sciences's share price for today is A$0.048.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Microba Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.039.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Microba Life Sciences EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MAP vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's EV-to-EBITDA falls into.
Microba Life Sciences's current Enterprise Value is A$25.69 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Microba Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-15.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences (ASX:MAP) has a EV-to-EBITDA of -1.67 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Microba Life Sciences. According to the industry distribution chart, Microba Life Sciences ranks #999999 out of 119 companies in the Medical Diagnostics & Research industry.
Is Microba Life Sciences' EV-to-EBITDA too high?
Microba Life Sciences' current EV-to-EBITDA is -1.67. Based on the distribution chart, Microba Life Sciences ranks #999999 out of 119 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Microba Life Sciences' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #999999 out of 119 companies for EV-to-EBITDA. This places Microba Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 15.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.76, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Microba Life Sciences. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current EV-to-EBITDA is -1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.23, compared to a current price of A$0.05 — trading 79.1% below its estimated fair value. The current EV-to-EBITDA is -1.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current EV-to-EBITDA is -1.67 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 
